secwatch.observer — SEC 8-K summary
======================================

Issuer:     TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK:        0000818686
Form:       8-K
Filed at:   2025-12-11T23:59:59+00:00
Accession:  0001193125-25-316063
Event type: debt
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants
--------------------------------------------------------------------------------

- Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.
- Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.
- Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.
- Consent fee of 0.08% of total commitments paid to lenders approving the amendment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818686/000119312525316063/0001193125-25-316063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818686/000119312525316063/d46386d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-316063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer